Additional file 1 of Vascular endothelial growth factor and the risk of venous thromboembolism: a genetic correlation and two-sample Mendelian randomization study

Additional file 1: Table S1. SNPs for VEGF in the forward MR analyses:Harmonized Data (r2< 0.01). SNP: single-nucleotide polymorphism;CHR: chromosome; POS: position; OA: other_allele; EA: effect_allele; SE: standard error; VEGF: vascular endothelialgrowth factor; VTE: venous thromboembolism; MR: Mendelian randomization; MAF: minor allele frequency; R2:variance for each SNP, R2 = 2×MAF× (1-MAF) × Beta2; F-statistic = R2 × (N-2)/(1-R2), N: the number of individualsin the exposure GWAS. $:SNPs were excluded after performing harmonizing procedure. *: DVT of the lower extremities and pulmonary embolism. #: DVT of the lower extremities. Table S2. SNPs for VTE in the reverse MR analyses: Harmonized Data(r2 < 0.001). SNP: single-nucleotide polymorphism; SE: standard error; VEGF: vascular endothelial growth factor; VTE: venous thromboembolism; MR: Mendelian randomization; MAF: minor allele frequency; R2:variance for each SNP, R2 = 2×MAF× (1-MAF) × Beta2; F-statistic = R2 × (N-2) / (1-R2), N: the number of individuals in the exposure GWAS. $: SNPs were excluded after performing harmonizing procedure. *: DVT of the lower extremities and pulmonary embolism. #:DVT of the lower extremities. Table S3.Causal associations of VEGF with risks of VTE, DVT_PE and DVT by forward MR analyses. SNP: single-nucleotide polymorphism; SE: standard error; VEGF: vascular endothelial growth factor;VTE: venous thromboembolism; IVW: inverse-variance weighted; WM: weighted median; PWM:penalty weighted median; CAUSE: causal analysis using summary effect estimates; MR-PRESSO: pleiotropy residual sum and outlier; OR: odds ratio; MR: Mendelian randomization; Q_pval: Pvalue of the Cochran Q statistic; I2= (Q-df)/Q×100%; P < 0.05 were considered statistically significant. *:DVT of the lower extremities and pulmonary embolism. #: DVT of the lower extremities. Table S4. Causal associations of VTE, DVT_PE and DVT with VEGF via reverse MR. SNP: single-nucleotide polymorphism; VEGF: vascular endothelial growth factor; VTE: venous thromboembolism; IVW: inverse-variance weighted; WM: weighted median; PWM:penalty weighted median; CAUSE: causal analysis using summary effect estimates; MR-PRESSO: pleiotropy residual sum and outlier; MR: Mendelian randomization; Q_pval: Pvalue of the Cochran Q statistic; I2= (Q-df)/Q×100%; P < 0.05 were considered statistically significant. *:DVT of the lower extremities and pulmonary embolism. #: DVT of the lower extremities. Table S5. The results of CAUSE analyses via forward MR. CAUSE: causal analysis using summary effect estimates; VEGF: vascular endothelial growth factor; VTE: venous thromboembolism; MR: Mendelian randomization. *: DVT of the lower extremities and pulmonary embolism. #: DVT of the lower extremities.Table S6. The results of CAUSE analyses via reverse MR.CAUSE: causal analysis using summary effect estimates; VEGF: vascular endothelial growth factor; VTE:venous thromboembolism; MR: Mendelian randomization.*: DVT of the lower extremities and pulmonary embolism. #: DVT of the lower extremities. Figure S1. MR Funnel plots (VEGF to VTE). VEGF: vascular endothelial growth factor; VTE:venous thromboembolism; MR: Mendelian randomization.Figure S2. MR Funnel plots (VTE to VEGF). VEGF: vascular endothelial growth factor; VTE:venous thromboembolism; MR: Mendelian randomization.